间充质干细胞
免疫学
免疫系统
医学
细胞疗法
人口
疾病
干细胞
自身免疫性疾病
间质细胞
癌症研究
生物
病理
抗体
细胞生物学
环境卫生
作者
Wenyan Tang,Jiahua Liu,Chun-Jin Peng,Lihua Yao,Jiesi Luo,Xi Sun,Yan-Lai Tang,Xue-Qun Luo
标识
DOI:10.1007/s00005-021-00603-y
摘要
Systemic lupus erythematosus (SLE) is a rare, heterogeneous autoimmune and autoinflammatory disease that affects both sexes and all races, although this disease exhibits its highest incidence/prevalence among the black population and shows a predilection for women of reproductive age. Although SLE has no cure, treatment can help decrease its signs and symptoms. Thus, we should focus primarily on personalized treatment. Mesenchymal stem/stromal cells (MSCs), which are multipotent cells capable of differentiating into osteoblasts, chondrocytes, adipocytes, and myoblasts, among other cell types, are potential candidates for use in a promising strategy to treat severe and refractory SLE. MSCs have an immunomodulatory function that can suppress the proliferation and activities of many immune cells, such as T lymphocytes, B lymphocytes, natural killer cells, macrophages and dendritic cells. Substantial progress has recently been made in MSC therapy, and experimental and clinical data suggest that such a therapy is a promising strategy for the treatment of severe and refractory SLE. In this review, we highlight the effects of MSCs on different immune cell types, describe the mechanisms underlying MSC-mediated immunoregulation, and discuss the treatment of SLE with MSCs from different sources in various animal models and clinical applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI